Biotech News

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Virios Therapeutics (VIRI)Virios Therapeutics2026-04-15 13:00 ESTFDA / regulatory

VIRI (VIRI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is viri.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VIRIVirios Therapeutics2026-05-18 12:45 EST

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

VIRIVirios Therapeutics2025-12-22 15:15 EST

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

ABUSArbutus2026-04-15 11:30 EST

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

ANTXAN2 Therapeutics2026-01-12 12:00 EST

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

COCPCocrystal Pharma2026-04-02 12:00 EST

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

OGENOragenics2026-03-10 12:30 EST

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

SPROSpero Therapeutics2025-12-19 08:00 EST

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

COCPCocrystal Pharma2025-12-18 13:00 EST

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

SPROSpero Therapeutics2026-06-17 17:36 EST

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

View all latest news

Virios Therapeutics

Virios Therapeutics is a biotechnology company focused on viral-trigger and inflammation biology, with an emphasis on chronic disease programs. Its story is built around a narrow disease hypothesis and early-stage development.

Recent company news

VIRIVirios Therapeutics2026-07-20 12:30 EST

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

VIRIVirios Therapeutics2026-06-30 12:45 EST

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

VIRIVirios Therapeutics2026-05-18 12:45 EST

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

VIRIVirios Therapeutics2026-05-14 12:30 EST

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

VIRIVirios Therapeutics2026-05-07 12:30 EST

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States